A new study published in JAMA Internal Medicine finds that the more patients learn about the scientific uncertainties surrounding a newly approved cancer drug, the less likely they are to want it — but researchers and clinicians say that's no reason to stay quiet.

The study involved 6,272 U.S. adults who were asked to imagine they were a patient with advanced non-small cell lung cancer deciding whether to try a hypothetical accelerated-approval drug. Participants who learned about evidence gaps — like the drug only being tested in a short, single-arm trial without proof it extended lives — became measurably less willing to try it. The effect grew with each additional uncertainty disclosed.

Experts stress that withholding information isn't the answer. Instead, the field needs better tools to help patients contextualize uncertainty — such as normalizing it as a standard part of the drug development process. This is especially timely as more cancer therapies enter the market via the FDA's accelerated approval pathway, often with key clinical questions still unanswered.

By the Numbers:

• 10 percentage points: drop in willingness after learning about just one uncertainty (67% → 57%)
• 19 percentage points: drop after learning about four uncertainties
• Less than 50%: share of clinical trial uncertainties included in prescribing information for new cancer drugs, per a prior study

Why it matters: As accelerated drug approvals become more common, patients and clinicians will increasingly face decisions with incomplete evidence. This study underscores the need for standardized, plain-language communication of drug uncertainties — and smarter ways to support informed decision-making without undermining patient agency.